Rethinking HS Disease Assessment: Bridging the Gap Between Inflammatory Mechanisms and Regulatory Endpoints
Time: 9:00 am
day: Day Two
Details:
- Understanding current clinical endpoint frameworks for Hidradenitis Suppurativa and their limitations in accurately measuring disease activity
- Emerging differences in regulatory view? A hot debate: HiSCR vs. IHS4
- Future direction: Aligning trial design with treatment goals putting inflammatory burden and PROs in the center
